Citations - Colombo Nicoletta

CONCLUSIONS: Almost half the patients without CA-125 progression had RECIST progression, and most of these had CA-125 within the normal range. Regular computed tomography imaging should be considered as part of surveillance in patients treated with or without maintenance olaparib rather than relying on CA-125 alone.... Read more
Published on: 2020-09-25
Source: Colombo Nicoletta
By: Angelina Tjokrowidjaja
CONCLUSIONS: Almost half the patients without CA-125 progression had RECIST progression, and most of these had CA-125 within the normal range. Regular computed tomography imaging should be considered as part of surveillance in patients treated with or without maintenance olaparib rather than relying on CA-125 alone.... Read more
Published on: 2020-09-25
Source: Colombo Nicoletta
By: Angelina Tjokrowidjaja
CONCLUSIONS: DFS was not the same by using an anthracycline-based or a gemcitabine-based adjuvant chemotherapy for patients with radically resected eULMS. The results of our study are in line with recent prospective controlled evidence in limb and superficial trunk soft tissue sarcomas. The role of anthracycline-based adjuvant chemotherapy should still... Read more
Published on: 2020-09-03
Source: Colombo Nicoletta
By: Giovanni Fucà
CONCLUSIONS: DFS was not the same by using an anthracycline-based or a gemcitabine-based adjuvant chemotherapy for patients with radically resected eULMS. The results of our study are in line with recent prospective controlled evidence in limb and superficial trunk soft tissue sarcomas. The role of anthracycline-based adjuvant chemotherapy should still... Read more
Published on: 2020-09-03
Source: Colombo Nicoletta
By: Giovanni Fucà
CONCLUSIONS: DFS was not the same by using an anthracycline-based or a gemcitabine-based adjuvant chemotherapy for patients with radically resected eULMS. The results of our study are in line with recent prospective controlled evidence in limb and superficial trunk soft tissue sarcomas. The role of anthracycline-based adjuvant chemotherapy should still... Read more
Published on: 2020-09-03
Source: Colombo Nicoletta
By: Giovanni Fucà
CONCLUSIONS: DFS was not the same by using an anthracycline-based or a gemcitabine-based adjuvant chemotherapy for patients with radically resected eULMS. The results of our study are in line with recent prospective controlled evidence in limb and superficial trunk soft tissue sarcomas. The role of anthracycline-based adjuvant chemotherapy should still... Read more
Published on: 2020-09-03
Source: Colombo Nicoletta
By: Giovanni Fucà
CONCLUSIONS: DFS was not the same by using an anthracycline-based or a gemcitabine-based adjuvant chemotherapy for patients with radically resected eULMS. The results of our study are in line with recent prospective controlled evidence in limb and superficial trunk soft tissue sarcomas. The role of anthracycline-based adjuvant chemotherapy should still... Read more
Published on: 2020-09-03
Source: Colombo Nicoletta
By: Giovanni Fucà
CONCLUSIONS: Efficacy, patient-centered outcomes, and safety of rucaparib were similar between age subgroups, indicating that all eligible women with recurrent ovarian cancer should be offered this therapeutic option, irrespective of age. https://clinicaltrials.gov/ct2/show/NCT01968213.... Read more
Published on: 2020-08-31
Source: Colombo Nicoletta
By: Nicoletta Colombo
We investigated the occurrence and management of therapy-related hematological disorders (tr-HDs) in women with epithelial ovarian cancer (EOC) exposed to poly-ADP-ribose polymerase inhibitors (PARPi), after previous chemotherapy. We analyzed 130 consecutive EOC patients treated with PARPi at the European Institute of Oncology, Milan. In line with the literature, overall survival... Read more
Published on: 2020-08-29
Source: Colombo Nicoletta
By: Elisabetta Todisco
CONCLUSIONS: A targeted cardioncological approach, in patients with evidence of cardiotoxicity during HER-2 inhibitor therapy, could favorably influence the oncological management of breast cancer patients, reducing the adverse cardiovascular impact of chemotherapy.... Read more
Published on: 2020-08-28
Source: Colombo Nicoletta
By: Iacopo Fabiani
CONCLUSION: The significant differences in QA-PFS and Q-TWiST confirm the benefit of rucaparib versus placebo in all predefined cohorts.... Read more
Published on: 2020-08-26
Source: Colombo Nicoletta
By: Amit M Oza
CONCLUSION: Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.... Read more
Published on: 2020-08-22
Source: Colombo Nicoletta
By: Bradley J Monk

Other Resources

Other Citations

Other Citations

News by Specialization

News by Specialization

Videos

Selection of Videos by Specialization

Latest News

Latest News

Translate »